COMMUNIQUÉS West-GlobeNewswire

Vera Therapeutics Appoints Christopher Hite to Board of Directors
05/03/2026
BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious [...]
NTG Nordic Transport Group A/S – Notice to convene the Annual General Meeting 2026
05/03/2026
Company announcement no. 4 – 26 5 March 2026 NTG Nordic Transport Group A/S – Notice to convene the Annual General Meeting 2026 The Annual General Meeting of NTG Nordic Transport Group A/S will be held on Friday, 27 [...]
ABLi Therapeutics to Present at the Citizens Life Sciences Conference
05/03/2026
ATLANTA and BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine Kinases (c-Abl [...]
Children’s Wisconsin and Xealth to Present Key Insights on Scalable Digital Patient Experience Programs at HIMSS26
05/03/2026
LAS VEGAS, March 05, 2026 (GLOBE NEWSWIRE) -- HIMSS— Xealth , the leading care orchestration platform for digital health, today announced that Xealth COO and Co-founder Aaron Sheedy will join Children’s Wisconsin Chief [...]
SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI
05/03/2026
Completion of enrollment marks a key milestone toward satisfying FDA post-approval requirements DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare [...]
Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting
05/03/2026
Grand Cayman, Cayman Island, March 05, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, reminds its shareholders of the [...]
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
05/03/2026
Proven experience in leveraging AI in biology will strengthen the board of directors as PacBio develops data tools to maximize the power of HiFi sequencing MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio ( [...]
Kestrel Therapeutics Announces IND Clearance by U.S. FDA of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, Enabling Initiation of Phase 1 Trial
05/03/2026
WATERTOWN, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Kestrel Therapeutics Inc. (“Kestrel” or the “Company”), a clinical stage biotechnology company developing next-generation small-molecule inhibitors targeting mutant [...]
CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature Agent
05/03/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 05, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the announcement issued by Sarborg Limited (“Sarborg”) regarding the [...]
Evaxion announces business update and full year 2025 financial results
05/03/2026
COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces [...]
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
05/03/2026
Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference CAMBRIDGE, Mass [...]
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
05/03/2026
HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
05/03/2026
Agreement Combines Tenaya’s Expertise in Identification and Validation of Genetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Million in Upfront [...]
Texas Original Opens Five New Locations to Expand Medical Marijuana Access Across the State
05/03/2026
Two satellite locations and three pickup sites bring life-changing medicine closer to patients and provide more flexibility BASTROP, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Texas Original , the state’s leading medical [...]
INVO Fertility Announces Availability of Advanced Incubation Technology at its Wisconsin Clinic
05/03/2026
Time-Lapse Incubation Provides Additional Cutting-Edge Solution for Patient Care SARASOTA, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare services [...]
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
05/03/2026
ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026 (GLOBE [...]
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
05/03/2026
Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women’s Hospital, Dr. Mina [...]
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
05/03/2026
Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 [...]
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
05/03/2026
Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement [...]

Pages